Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

Filippo Montemurro, Valentina Rossi, Elena Geuna, Giorgio Valabrega, Rossella Martinello, Andrea Milani, Massimo Aglietta

Research output: Contribution to journalArticle

Abstract

Introduction: Endocrine therapy is a fundamental component of the therapeutic repertoire for treatment of metastatic, hormone receptor-positive breast cancer. Inevitably, however, tumors develop resistance to these compounds, and overcoming this phenomenon is a key motivator of research in this field. Areas covered: This review summarizes the current status of endocrine therapy for the treatment of metastatic disease, with a main focus on postmenopausal patients. Furthermore, strategies that could potentially sustain endocrine resistance and future perspectives in this direction are also to be described. Relevant references were identified by PubMed searches and from the abstract books of the annual meetings of The European Society of Clinical Oncology (ESMO), The American Society of Clinical Oncology (ASCO) and from the San Antonio Breast Cancer Symposia. Expert opinion: Combinations of endocrine therapy with HER2 targeting agents, as well as with compounds that can interfere with PI3K/Akt/mTOR signaling, are two promising strategies for delaying or overcoming endocrine resistance, mediated by these relevant biological pathways. Due to increased costs and the burden of toxicity associated with these combination therapies, compared to endocrine therapy alone, it is imperative to concentrate efforts on establishing biomarkers that can predict efficacy.

Original languageEnglish
Pages (from-to)2143-2156
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number15
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Aromatase inhibitors
  • Endocrine resistance
  • Everolimus
  • Fulvestrant
  • Gefitinib
  • Lapatinib
  • Metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this